Silence Therapeutics plc (SLN) Reaches New 12-Month High at $210.00
Silence Therapeutics plc (LON:SLN) hit a new 52-week high during trading on Wednesday . The stock traded as high as GBX 210 ($2.79) and last traded at GBX 210 ($2.79), with a volume of 45,394 shares. The stock had previously closed at GBX 195.88 ($2.60).
The company has a 50 day moving average of GBX 176.47 and a 200 day moving average of GBX 118.85. The firm’s market cap is GBX 141.15 million.
In other Silence Therapeutics plc news, insider Andy Richards acquired 7,000 shares of the company’s stock in a transaction on Monday, July 31st. The shares were purchased at an average cost of GBX 147 ($1.95) per share, with a total value of £10,290 ($13,649.03). Also, insider Alistair Gray acquired 3,848 shares of the company’s stock in a transaction on Wednesday, August 2nd. The stock was acquired at an average cost of GBX 130 ($1.72) per share, for a total transaction of £5,002.40 ($6,635.36).
Silence Therapeutics plc Company Profile
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.
Receive News & Ratings for Silence Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics plc and related companies with Analyst Ratings Network's FREE daily email newsletter.